Alzheimer's Disease Trial, Recruiting NCT05010603 Sponsor: Columbia University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT05010603
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Alzheimer's disease (either confirmed or probable), or a related brain condition such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD)
  • You have at least one living brother or sister who has been diagnosed with probable or possible Alzheimer's disease
  • You have a third living family member who either has Alzheimer's disease (diagnosed at age 50 or older) or does not have the condition but is aged 60 or older
  • You are in the same generation as the main participant in the study, and you have someone who knows you well (a "companion") who can provide information about you
  • You are able to give your own consent to join the study, OR if you are not able to do so, there is someone legally able to give consent on your behalf (such as a family member or legal representative)

Who may not be able to join:

  • There is no suitable person available who knows you well enough to provide information about you
  • Your diagnosis of Alzheimer's disease or a related condition is not clear enough to confirm
  • You have another condition that could explain your symptoms instead
  • You do not wish to take part
  • You do not have a living brother or sister with Alzheimer's disease or a related condition (except in certain cases of sporadic FTD or sporadic LBD — confirm with trial site)
  • You are unable to give your own consent and there is no family member or legal representative available to consent on your behalf

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Richard P. Mayeux, MD, MSc, Columbia University

Phone: 212-305-5953

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 November 2016
Est. completion
30 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Total number of genes identified to be associated with the risk of AD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov